Literature DB >> 25739961

NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

Mauro Di Pilato1, Ernesto Mejías-Pérez1, Manuela Zonca2, Beatriz Perdiguero1, Carmen Elena Gómez1, Marianna Trakala3, Jacobo Nieto1, José Luis Nájera1, Carlos Oscar S Sorzano4, Christophe Combadière5, Giuseppe Pantaleo6, Lourdes Planelles2, Mariano Esteban7.   

Abstract

Neutrophils are antigen-transporting cells that generate vaccinia virus (VACV)-specific T-cell responses, yet how VACV modulates neutrophil recruitment and its significance in the immune response are unknown. We generated an attenuated VACV strain that expresses HIV-1 clade C antigens but lacks three specific viral genes (A52R, K7R, and B15R). We found that these genes act together to inhibit the NFκB signaling pathway. Triple ablation in modified virus restored NFκB function in macrophages. After virus infection of mice, NFκB pathway activation led to expression of several cytokines/chemokines that increased the migration of neutrophil populations (Nα and Nβ) to the infection site. Nβ cells displayed features of antigen-presenting cells and activated virus-specific CD8 T cells. Enhanced neutrophil trafficking to the infection site correlated with an increased T-cell response to HIV vector-delivered antigens. These results identify a mechanism for poxvirus-induced immune response and alternatives for vaccine vector design.

Entities:  

Keywords:  HIV; NFκB; neutrophils; vaccine; vaccinia virus

Mesh:

Substances:

Year:  2015        PMID: 25739961      PMCID: PMC4371968          DOI: 10.1073/pnas.1424341112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

Review 1.  Structures of the toll-like receptor family and its ligand complexes.

Authors:  Mi Sun Jin; Jie-Oh Lee
Journal:  Immunity       Date:  2008-08-15       Impact factor: 31.745

2.  Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3.

Authors:  Arnout P Kalverda; Gary S Thompson; Andre Vogel; Martina Schröder; Andrew G Bowie; Amir R Khan; Steve W Homans
Journal:  J Mol Biol       Date:  2008-09-27       Impact factor: 5.469

3.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

4.  Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model.

Authors:  Jens Wild; Kurt Bieler; Josef Köstler; Marie-Joelle Frachette; Simon Jeffs; Sueli Vieira; Mariano Esteban; Peter Liljeström; Guiseppe Pantaleo; Hans Wolf; Ralf Wagner
Journal:  Viral Immunol       Date:  2009-10       Impact factor: 2.257

5.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.

Authors:  Zvi G Fridlender; Jing Sun; Samuel Kim; Veena Kapoor; Guanjun Cheng; Leona Ling; G Scott Worthen; Steven M Albelda
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

6.  Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression.

Authors:  Michael H Lehmann; Wolfgang Kastenmuller; Judith D Kandemir; Florian Brandt; Yasemin Suezer; Gerd Sutter
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

7.  Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways.

Authors:  Chad Myskiw; Janilyn Arsenio; Rebekah van Bruggen; Yvon Deschambault; Jingxin Cao
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

8.  Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection.

Authors:  Martha A Hutchens; Kathryn E Luker; Joanne Sonstein; Gabriel Núñez; Jeffrey L Curtis; Gary D Luker
Journal:  PLoS Pathog       Date:  2008-09-19       Impact factor: 6.823

9.  Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.

Authors:  Julie Delaloye; Thierry Roger; Quynh-Giao Steiner-Tardivel; Didier Le Roy; Marlies Knaup Reymond; Shizuo Akira; Virginie Petrilli; Carmen E Gomez; Beatriz Perdiguero; Jürg Tschopp; Giuseppe Pantaleo; Mariano Esteban; Thierry Calandra
Journal:  PLoS Pathog       Date:  2009-06-19       Impact factor: 6.823

10.  Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis.

Authors:  Stephen C Graham; Mohammad W Bahar; Samantha Cooray; Ron A-J Chen; Daniel M Whalen; Nicola G A Abrescia; David Alderton; Raymond J Owens; David I Stuart; Geoffrey L Smith; Jonathan M Grimes
Journal:  PLoS Pathog       Date:  2008-08-15       Impact factor: 6.823

View more
  14 in total

1.  Neutrophil and vaccine.

Authors:  Mauro Di Pilato; Mariano Esteban
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.

Authors:  Mauro Di Pilato; Ernesto Mejías-Pérez; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

3.  Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Authors:  Adrián Lázaro-Frías; Sergio Gómez-Medina; Lucas Sánchez-Sampedro; Karl Ljungberg; Mart Ustav; Peter Liljeström; César Muñoz-Fontela; Mariano Esteban; Juan García-Arriaza
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 4.  Cutting both ways: the innate immune response to oncolytic virotherapy.

Authors:  David Mealiea; J Andrea McCart
Journal:  Cancer Gene Ther       Date:  2021-08-27       Impact factor: 5.854

5.  Essential Role of Neutrophils in the Protective Immune Response Induced by a Live Attenuated Leishmania Vaccine.

Authors:  Parna Bhattacharya; Ranadhir Dey; Ankit Saxena; Subir Karmakar; Nevien Ismail; Sreenivas Gannavaram; Pradeep K Dagur; Monika Satoskar; Sanika Satoskar; Silvia De Paoli; Kazuyo Takeda; John Philip McCoy; Hira L Nakhasi
Journal:  J Immunol       Date:  2020-11-11       Impact factor: 5.422

6.  Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.

Authors:  Ernesto Mejías-Pérez; Liliana Carreño-Fuentes; Mariano Esteban
Journal:  Mol Ther Oncolytics       Date:  2017-12-05       Impact factor: 7.200

7.  Interleukin 10 modulation of neutrophil subsets infiltrating lungs during Streptococcus pneumoniae infection.

Authors:  Hernán F Peñaloza; Francisco J Salazar-Echegarai; Susan M Bueno
Journal:  Biochem Biophys Rep       Date:  2017-11-22

Review 8.  Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity.

Authors:  Ulrich E Schaible; Lara Linnemann; Natalja Redinger; Emmanuel C Patin; Tobias Dallenga
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

9.  Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Cristina Sánchez-Corzo; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  Viruses       Date:  2017-12-27       Impact factor: 5.048

10.  Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.

Authors:  María Q Marín; Patricia Pérez; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban; Juan García-Arriaza
Journal:  Viruses       Date:  2018-08-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.